New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual. Reading time 2 minutes An experimental “off-the-shelf” vaccine for recurring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback